Chengdu – September 16, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) said phase III results for its HER2-targeted antibody-drug conjugate trastuzumab botidotin have been published in the Journal of Clinical Oncology, a journal with an impact factor of 44.7, after the drug outperformed Roche's trastuzumab emtansine (T-DM1) in a head-to-head trial and secured approval from China's National Medical Products Administration.

Cambridge, Massachusetts – September 11, 2026 -- Harbour BioMed (HKEX: 02142) and partner Windward Bio reported positive Phase 2 interim results for HBM9378/WIN378, a twice-yearly TSLP-blocking antibody, from the 147-patient POLARIS-1 asthma trial, clearing the path for two Phase 3 studies.